List of participating centers, investigators and staff: Cincinnati Children's Hospital Medical Center, Cincinnati, OH: Jens Goebel; Cleveland Clinic, Cleveland, OH: Robert Fairchild, Richard Fatica, Stuart Flechner, David Goldfarb, Karen Keslar, Venkatesh Krishnamurthi, Saul Nurko, Emilio Poggio and Brian Stephany; Cornell University School of Medicine, New York, NY: M. Suthanthiran; Emory University Medical Center, Atlanta, GA: Robert Bray, Howie Gebel and Kenneth A. Newell; Egleston Children's Hospital of Emory University, Atlanta, GA: Barry L. Warshaw; Icahn School of Medicine at Mount Sinai, New York, NY: Enver Akalin, Scott Ames, Jonathan Bromberg, Graciela DeBoccardo, Rajani Dinavahi, Peter S. Heeger, Susan Lerner, Marvin Lin, Barbara Murphy, Vinay Nair, Denise Peace, Bernd Schroppel and Vinita Seghal; Transplantation Branch, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD: Nancy D. Bridges and Yvonne Morrison; Rho, Chapel Hill, NC: David Ikle, Alexander Lockhardt, Katie Poole and Michael Riggs; University Hospitals Case Medical Center, Cleveland, OH: Mark Aeder, Joshua Augustine, Donald Hricik, Aparna Padiyar and James Schulak; University of Utah School of Medicine, Salt Lake City, UT: Fuad Shihab; University of Manitoba, Winnipeg, Manitoba, Canada: Patricia Birk, Ian Gibson, Peter Nickerson and David Rush; Yale University School of Medicine, New Haven, CT: Richard Formica and Danielle Jacques.
Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury
Version of Record online: 22 AUG 2013
© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 13, Issue 10, pages 2634–2644, October 2013
How to Cite
Hricik, D. E., Nickerson, P., Formica, R. N., Poggio, E. D., Rush, D., Newell, K. A., Goebel, J., Gibson, I. W., Fairchild, R. L., Riggs, M., Spain, K., Ikle, D., Bridges, N. D., Heeger, P. S. and for the CTOT-01 consortium (2013), Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury. American Journal of Transplantation, 13: 2634–2644. doi: 10.1111/ajt.12426
- Issue online: 24 SEP 2013
- Version of Record online: 22 AUG 2013
- Manuscript Accepted: 11 MAY 2013
- Manuscript Revised: 3 MAY 2013
- Manuscript Received: 11 MAR 2013
- National Institutes of Health. Grant Number: AI63594-06
Additional Supporting Information may be found in the online version of this article at the publisher's web site.
Figure S1: Dot plot correlating individual values of 6 months urinary CXCL9 with individual “i” and “t” scores from simultaneous surveillance biopsies excluding those with Banff >1A rejection on the protocol biopsy. p-Values of 0.0673 and 0.0261 refer to ANOVAs comparing the means across Banff scores for each panel.
Table S1: PCR primer sequences.
Table S2: Correlation coefficients among urinary mRNAs tested (correlations >0.5 are in bold type).
Table S3: Logistic regression models substituting perforin mRNA for granzyme B mRNA to diagnose Banff >1A acute rejection.
Table S4: Multivariate logistic regression models correlating urinary biomarkers with Banff >1A rejection.
Table S5: Multivariate logistic regression models correlating urinary biomarkers with Banff >1A rejection removing all cases of infection.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.